<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        472-149-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BIOCAFFCIT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CAFFEINE CITRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2393.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharmaceutical Solution Industries (PSI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 444]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharmaceutical Solution Industries (PSI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06BC01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Biocaffcit contains the active substance caffeine citrate, which is a stimulant of the central nervous&nbsp;<br />system, belonging to a group of medicines called methylxanthines.&nbsp;<br />- Biocaffcit is used in the treatment of interrupted breathing in premature babies (primary apnoea of&nbsp;<br />premature newborns).&nbsp;<br />These short periods when premature babies stop breathing are due to the baby&rsquo;s breathing centres&nbsp;<br />not being fully developed.&nbsp;<br />This medicine has been shown to reduce the number of episodes of interrupted breathing in&nbsp;<br />premature newborns.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Biocaffcit:&nbsp;</strong><br />If your newborn is allergic to caffeine citrate or any of the other ingredients of this medicine (listed in section 6).&nbsp;</p><p><strong>Warnings and precautions&nbsp;</strong><br />Talk to your baby&rsquo;s doctor before your newborn is given Biocaffcit.&nbsp;<br />Prior to starting treatment by Biocaffcit other causes of apnoea should have been excluded or&nbsp;<br />properly treated by your baby&rsquo;s doctor.&nbsp;<br />Biocaffcit should be used with caution. Please inform your baby&rsquo;s doctor:&nbsp;<br />If your newborn suffers from seizures&nbsp;<br />If your newborn suffers from any heart disease&nbsp;<br />If your newborn has kidney or liver problems&nbsp;<br />If your newborn has frequent regurgitation&nbsp;<br />If your newborn produces more urine than usual&nbsp;<br />If your newborn has a reduced weight gain or food intake&nbsp;<br />If you (the mother) consumed caffeine prior to delivery&nbsp;</p><p><strong>Other medicines and Biocaffcit</strong><br />Tell your baby&rsquo;s doctor if your newborn is taking, have recently taken or might take any other&nbsp;<br />medicines.&nbsp;<br />Please inform your baby&rsquo;s doctor if your newborn has been previously treated with theophylline.&nbsp;<br />Do not use the following medicines during the treatment with Biocaffcit without talking to your&nbsp;<br />baby&rsquo;s doctor. The doctor may need to adjust the dose or change one of the medicines to&nbsp;<br />something else:&nbsp;<br />theophylline (used to treat breathing difficulties)&nbsp;<br />doxapram (used to treat breathing difficulties)&nbsp;<br />cimetidine (used to treat gastric disease)&nbsp;<br />ketoconazole (used to treat fungine infections)&nbsp;<br />phenobarbital (used to treat epilepsy)&nbsp;<br />phenytoin (used to treat epilepsy)&nbsp;<br />This medicine may increase the risk for serious intestinal disease with bloody stools (necrotising&nbsp;<br />enterocolitis) when administered with medicines used to treat gastric disease (such as&nbsp;<br />antihistamine H2 receptor blockers or proton-pump inhibitors that reduces gastric acid secretion).&nbsp;</p><p><br /><strong>Pregnancy and breast-feeding&nbsp;</strong><br />If you (the mother) are breast-feeding while your infant is treated with Biocaffcit, you should not&nbsp;<br />drink coffee or take any other high caffeine product as caffeine passes into breast milk.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Biocaffcit should only be used in a neonatal intensive care unit in which adequate facilities&nbsp;<br />are available for patient surveillance and monitoring. Treatment should be initiated under&nbsp;<br />supervision of a physician experienced in neonatal intensive care.<br />Dose Your baby&rsquo;s doctor will prescribe the right amount of Biocaffcit based on your baby&rsquo;s weight.<br />The starting dose is 20 mg per kg body weight (equivalent to 1 ml per kg body weight).&nbsp;<br />The maintenance dose is 5 mg per kg body weight (equivalent to 0.25 ml per kg body weight) every&nbsp;<br />24 hours.&nbsp;</p><p>Route and method of administration&nbsp;<br />Biocaffcit will be infused by controlled intravenous infusion, using a syringe infusion pump or other&nbsp;<br />metered infusion device. This method is also known as &ldquo;a drip&rdquo;.&nbsp;<br />Some of the doses (maintenance doses) may be given by mouth.&nbsp;<br />It may be needed that your baby&rsquo;s doctor decides to check the levels of caffeine in a blood test&nbsp;<br />periodically throughout treatment to avoid toxicity.&nbsp;</p><p><strong>Duration of treatment&nbsp;</strong><br />Your baby&rsquo;s doctor will decide exactly how long your newborn must continue therapy with Biocaffcit.&nbsp;<br />If your baby has 5 to 7 days without apnoea attacks, the doctor will stop the treatment.</p><p><br /><strong>If your newborn receives more Biocaffcit than he/she should&nbsp;</strong><br />Your newborn may experience fever, rapid breathing (tachypnoea), jitteriness, muscular tremor,&nbsp;<br />vomiting, high blood levels of sugar (hyperglycemia), low blood levels of potassium (hypokalaemia),&nbsp;<br />high blood levels of certain chemicals (urea), elevated number of certain cells (leukocyte) in blood&nbsp;<br />and seizures if he/she receives more caffeine citrate than he/she should.&nbsp;<br />In the event of this happening treatment with Biocaffcit should be stopped immediately and your&nbsp;<br />baby&rsquo;s doctor should treat the overdose.&nbsp;<br />If you have any further questions on the use of this medicinal product, ask your baby&rsquo;s doctor.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;<br />However, it is difficult to distinguish them from frequent complications occurring in premature babies&nbsp;<br />and complications due to the disease.&nbsp;<br />While under treatment with Biocaffcit, your newborn may experience some of the following&nbsp;reactions:&nbsp;</p><p><br /><strong>Serious side effects&nbsp;</strong><br />Side effects where the frequency cannot be estimated from the available data&nbsp;<br />. serious intestinal disease with bloody stools (necrotising enterocolitis)&nbsp;<br />The following other side effects may also be considered serious by your baby&rsquo;s doctor in the&nbsp;<br />context of the global clinical evaluation.&nbsp;</p><p><strong>Other side effects&nbsp;</strong><br />Common reported side effects (may affect up to 1 in 10 people)&nbsp;<br />. local inflammatory reactions at the infusion site&nbsp;<br />. cardiac disorders such as fast heart beat (tachycardia)&nbsp;<br />. changes of sugar in blood or serum (hyperglycaemia)&nbsp;<br />Uncommon reported side effects (may affect up to 1 in 100 people)&nbsp;<br />. stimulation of central nervous system such as convulsion&nbsp;<br />. cardiac disorders such as irregular heart beat (arrhythmia)&nbsp;<br /><strong>Rare </strong>reported side effects (may affect up to 1 in 1,000 people)&nbsp;</p><p>. allergic reactions&nbsp;</p><p><br /><strong>Side effects</strong> where the frequency cannot be estimated from the available data&nbsp;<br />. bloodstream infection (sepsis)&nbsp;<br />. changes of sugar in blood or serum (hypoglycaemia), failure to grow, feeding intolerance&nbsp;<br />. stimulation of central nervous system such as irritability, nervousness and restlessness; brain injury&nbsp;<br />. deafness&nbsp;<br />. regurgitation, increase in stomach aspirate&nbsp;<br />. increase of urine flow, increase of certain urine components (sodium and calcium)&nbsp;<br />. changes in blood tests (reduced levels of haemoglobin after prolonged treatment and reduced thyroid&nbsp;<br />hormone at the start of treatment)&nbsp;</p><p><br /><strong>Reporting of side effects&nbsp;</strong><br />If your newborn gets any side effects, talk to your baby&rsquo;s doctor. This includes any possible side&nbsp;<br />effects not listed in this leaflet.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the reach and sight of children.<br />Do not use after the expiry date which is stated on the label.&nbsp;<br />Do not store above 30&deg;C.&nbsp;<br />Vials of Biocaffcit must be inspected visually for particulate matter &amp; discolouration prior to&nbsp;<br />administration.<br />In case of dilution, the diluted solution could be stored at temperature 25&deg;C or between 2-8&deg;C, and&nbsp;<br />used within 24 hours of dilution.<br />After opening the vials, the medicinal product should be used immediately.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; The active substance is caffeine citrate.<br />Each ml contains 20 mg caffeine citrate (equivalent to 10 mg caffeine).<br />&bull; The other ingredients are citric acid monohydrate, Sodium Citrate dihydrate &amp; water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Biocaffcit is a clear, colourless solution for infusion and oral solution. 
Pack size: 10 Glass vials / Pack
Infusion Preparation
Ideally, Biocaffcit Infusion should be prepared shortly before use.
Instruction for handling
Chemical and physical compatibility of the diluted solution has been demonstrated for 24 hours at 
25°C and at 2 - 8°C. 
In the following solutions: 0.9% Sodium Chloride, 5% glucose & 10% Calcium Gluconate. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer<br />Pharmaceutical Solutions Industry Ltd.<br />Industrial Estate, Phase-2,&nbsp;<br />Road No. 208, Str. - 203<br />P O Box 17476<br />Jeddah 21484<br />Western Province<br />Saudi Arabia<br />Phone: +966-12-6361383<br />FAX: +966-12-6379460<br />Website: http://www.psiltd.com</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>For Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>* Fax: +966-11-205-7662</p><p>* Reporting hotline: 19999.</p><p>* E-mail: npc.drug@sfda.gov.sa</p><p>* Website: www.sfda.gov.sa/npc</p><p>Other GCC States:<br />Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>- بيوكافست يحتوي على المادة الفعالة سترات الكافيين، وهو منشط للجهاز العصبي المركزي، وينتمي إلى مجموعة من الأدوية تسمى ميثيل زانسينز.<br />- بيوكافست يستخدم في علاج انقطاع التنفس لفترات قصيره عند الأطفال المبتسرين، ويرجع انقطاع التنفس في هذه الحالات الى عدم اكتمال&nbsp;<br />نمو مراكز التنفس عند الأطفال<br />وقد تبين أن هذا الدواء يستخدم للحد من عدد حالات انقطاع التنفس عند حديثي الولادة المبتسرين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول بيوكافست</strong><br />إذا كان طفلك حديث الولادة لديه حساسية من سترات الكافيين أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)</p><p><br /><strong>التحذيرات والاحتياطات</strong><br />تحدث مع طبيب طفلك قبل إعطاءه بيوكافست</p><p>قبل البدء في العلاج باستخدام بيوكافست يرجى التأكد من أن انقطاع النفس لأسباب أخرى قد تم استبعاده أو معالجته بشكل صحيح من قبل&nbsp;<br />طبيب طفلك</p><p><br /><strong>يجب استخدام بيوكافست بحذر. ويرجى إبلاغ طبيب طفلك في هذه الحالات :</strong><br />إذا كان طفلك حديث الولادة يعاني من نوبات صرع<br />إذا كان طفلك حديث الولادة يعاني من أي مرض بالقلب<br />إذا كان طفلك حديث الولادة لديه مشاكل في الكلى أو الكبد<br />إذا كان طفلك حديث الولادة لديه ارتجاع متكرر<br />إذا كان طفلك حديث الولادة يعاني من زيادة معدل التبول &quot; أكثر من المعتاد&quot;<br />إذا كان طفلك حديث الولادة لديه زيادة في الوزن أوفى تناول الطعام<br />إذا كانت الأم تتناول الكافيين قبل عمليه الولادة</p><p>&nbsp;</p><p><strong>أدوية أخرى و بيوكافست</strong><br />أخبر طبيب طفلك إذا كان المولود يأخذ أوأخذ مؤخرا أو قد يأخذ أي أدوية أخرى.<br />يرجى إبلاغ طبيب طفلك إذا كان طفلك حديث الولادة قد تم علاجه من قبل باستخدام الثيوفيلين.<br />لا تستخدم الأدوية التالية أثناء العلاج بـ بيوكافست دون التحدث إلى طبيب طفلك. قد يحتاج الطبيب إلى ضبط الجرعة أو تغيير أحد الأدوية&nbsp;<br />إلى دواء آخر:<br />الثيوفيلين (يستخدم لعلاج صعوبات التنفس)<br />دوكسابرام (يستخدم لعلاج صعوبات التنفس)<br />سيميتيدين (يستخدم لعلاج أمراض المعدة)<br />كيتوكونازول (يستخدم لعلاج العدوى الفطرية)<br />فينوباربيتال (يستخدم لعلاج الصرع)<br />فينيتوين (يستخدم لعلاج الصرع)<br />هذا الدواء قد يزيد من احتماليه الإصابة بأمراض معوية خطيرة مصاحبه ببراز دموي (التهاب الأمعاء التقرحى) عندما يتم تناوله مع الأدوية&nbsp;<br />المستخدمة لعلاج أمراض المعدة (مثل موانع مستقبلات مضادات الهيستامين ۲H أو مثبطات مضخة البروتون التي تقلل من إفراز حمض المعدة).<br />الحمل والرضاعة الطبيعية<br />إذا كانت الأم تقوم بإرضاع طفلها &quot; الرضاعة الطبيعية&quot; ويتم علاج هذا الطفل باستخدام بيوكافست ، يجب على الأم ألا تشرب القهوة ولا&nbsp;<br />تأخذ أي منتج آخر يحتوي على تركيز عالي من الكافيين حيث أن الكافيين سيمر في حليب الثدي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>وينبغي ألا يستخدم بيوكافست إلا في وحدة العناية المركزة لحديثي الولادة والتي تتوفر فيها الوسائل الكافية لمراقبة المرضى.&nbsp;<br />وينبغي أن يبدأ العلاج تحت إشراف طبيب من ذوي الخبرة في الرعاية المركزة لحديثي الولادة.</p><p><strong>الجرعة</strong><br />سيصف طبيب طفلك الجرعة الصحيحة من بيوكافست بناء على وزن طفلك.<br />الجرعة المبدئية هي ۲۰ مجم لكل كجم من وزن الجسم (أي ما يعادل ۱ مل لكل كجم من وزن الجسم).<br />جرعة المداومة هي ٥ مجم لكل كجم من وزن الجسم (أي ما يعادل ۰٫۲٥ مل لكل كجم من وزن الجسم) كل ۲٤ ساعة.</p><p><strong>طريقه تناول بيوكافست</strong><br />يتم أخد بيوكافست عن طريق التسريب الوريدي وذلك باستخدام مضخة الحقن أو أي جهاز أخر للتسريب المقنن. ويعرف هذا الأسلوب أيضا&nbsp;<br />باسم&quot;بالتنقيط&quot;.<br />ويمكن إعطاء بعض الجرعات (جرعات المداومة) عن طريق الفم.<br />قد يكون من الضروري أن يقرر طبيب طفلك فحص مستويات الكافيين في الدم بشكل دوري طوال فترة العلاج لتجنب السمية.</p><p><strong>مدة العلاج</strong><br />سوف يقرر طبيب طفلك بالضبط المدة التي يجب أن يستمر طفلك حديث الولادة في العلاج باستخدام بيوكافست.<br />إذا ظل طفلك لمده تتراوح بين ٥ إلى ۷ أيام دون نوبات انقطاع النفس سيقوم الطبيب بالتوقف عن العلاج.</p><p>&nbsp;</p><p><strong>عند تناول الطفل حديث الولادة لـ بيوكافست بكميه أكثر مما ينبغي</strong><br />قد يعاني طفلك حديث الولادة من الحمى والتنفس السريع (تسارع التنفس)، والارتعاش، ورعاش العضلات، والتقيؤ، وارتفاع مستويات السكر&nbsp;<br />في الدم (ارتفاع السكر في الدم)، وانخفاض مستوي البوتاسيوم بالدم (نقص بوتاسيوم الدم)، وارتفاع مستويات بعض المواد الكيميائية بالدم&nbsp;<br />(اليوريا)، وارتفاع عدد بعض الخلايا (الكريات البيضاء) في الدم ونوبات إذا كان / كانت تتلقى كميه من سترات الكافيين أكثر مما ينبغي.<br />في حالة حدوث ذلك أثناء العلاج بـ بيوكافست يجب فورا وقف العلاج وعلى طبيب طفلك أن يقوم بعلاج الجرعة الزائدة.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا المنتج الطبي، اسأل طبيب طفلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية، والتي قد لا تظهر على كل شخص يتناول هذا الدواء.<br />ومع ذلك، فإنه من الصعب التمييز بينها وبين المضاعفات المتكررة والتي تحدث في الأطفال المبتسرين والمضاعفات الناجمة عن المرض.<br />وأثناء العلاج باستخدام بيوكافست ، قد يواجه حديثي الولادة بعض الأثار الجانبية التالية:</p><p><strong>آثار جانبية خطيرة</strong><br />الآثار الجانبية التي لا يمكن تقدير معدل حدوثها من البيانات المتاحة<br />. مرض معوي خطير مع براز دموي (التهاب الأمعاء التقرحى)<br />الآثار الجانبية التالية قد تعتبر خطيرة أيضا من قبل طبيب طفلك وذلك في سياق التقييم السريري العالمي.</p><p><strong>الآثار الجانبية الأخرى</strong><br /><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر على ما يصل إلى ۱ من كل ۱۰ أشخاص)<br />. الالتهابات الموضعية في موقع التسريب<br />. اضطرابات القلب مثل تسارع ضربات القلب (عدم انتظام دقات القلب)<br />. تغير في معدل السكر في الدم أو المصل (زيادة نسبه السكر بالدم)</p><p><strong>الآثار الجانبية الغير شائعة</strong> (قد تؤثر على ما يصل إلى ۱ من كل ۱۰۰ شخص)<br />. تحفيز الجهاز العصبي المركزي كحدوث تشنجات<br />. اضطرابات القلب مثل عدم انتظام ضربات القلب&nbsp;<br /><strong>الآثار الجانبية النادرة </strong>(قد تؤثر على ما يصل إلى ۱ في ۱۰۰۰ شخص)<br />. الحساسية</p><p><strong>الآثار الجانبية التي لا يمكن تقدير معدل حدوثها من البيانات المتاحة</strong><br />. عدوى الدم (تعفن الدم)<br />. تغير معدل السكر في الدم أو المصل (نقص نسبه السكر بالدم)، وعدم النمو، عدم تحمل الطعام<br />. تحفيز الجهاز العصبي المركزي مثل التهيج، والعصبية وعدم الارتياح، إصابة الدماغ<br />. صمم<br />. ارتجاع (زيادة في نضح المعدة )<br />. زيادة تدفق البول، وزيادة بعض مكونات البول (الصوديوم والكالسيوم)<br />. تغيرات في اختبارات الدم (انخفاض مستويات الهيموجلوبين بعد العلاج لفترات طويلة وانخفاض هرمون الغدة الدرقية في بداية العلاج)</p><p><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا حدث لطفلك حديث الولادة أي آثار جانبية، تحدث مع طبيب طفلك. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيدا عن متناول الأطفال. لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق. لا تحفظ الدواء في درجه حرارة تزيد عن ۳۰ درجة مئوية. يجب فحص الفيال المحتوية على بيوكافست بصريا بخصوص الجسيمات الصغيرة وتغير لونه قبل إستخدامه في حالة التخفيف، يمكن حفظ المحلول المخفف عند درجة حرارة ۲٥ درجة مئوية أو بين ۲ ۸- درجة مئوية ، ويستخدم خلال ۲٤ ساعة من التخفيف. يجب استخدام المنتج الطبي فورا بعد فتح الـڤيال</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>بيوكافست يحتوي على &bull; المادة الفعالة هي سترات الكافيين. كل مل يحتوي على ۲۰ مجم سترات الكافيين (أي ما يعادل ۱۰ مجم كافيين). &bull; المكونات الأخرى: حامض الستريك أحادي التميؤ، سترات الصوديوم ثنائى التميؤ ، ماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف يبدو بيوكافست ، وما هى محتوايات العبوة .<br />بيوكافست هو محلول مائي شفاف ، عديم اللون يستخدم عن طريق الفم أو عن طريق التسريب الوريدي<br />محتوي العبوة: ۱۰ فيال زجاجية فى العبوة الخارجية.<br />إعداد المستحضر للتسريب الوريدي<br />الطريقة المثالية، يجب أن يتم إعداد المستحضر قبل وقت قصير من الاستخدام في حال استخدامه للتسريب الوريدي<br />تعليمات الاستخدام<br />مستحضر بيوكافست بعد التخفيف متوافق كيميائيا وفيزيائيا لمدة ۲٤ ساعة عند درجة حرارة كل من۲٥: درجة مئوية و بين ۸-۲ درجة&nbsp;<br />مئوية في المحاليل التالية: ٪۰٫۹ كلوريد الصوديوم، ٪٥ جلوكوز و ٪۱۰ جلوكونات الكالسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مصنع المحاليل الطبية.<br />العنوان:المنطقة الصناعية، المرحلة الثانية.<br />طريق رقم ،۲۰۸ شارع ۲۰۳<br />صندوق بريد ۱۷٤۷٦ جدة .۲۱٤۸٤<br />المنطقة الغربية<br />المملكة العربية السعودية<br />الهاتف: +۹٦٦-۱۲-٦۳٦۱۳۸۳<br />الفاكس: +۹٦٦-۱۲-٦۳۷۹٤٦۰<br />الموقع الالكتروني: http://www.psiltd.com</p><p>&nbsp;</p><p><br />للإبلاغ عن أي أعراض جانبیة:</p><p><br />المملكة العربیة السعودیة<br />المركز الوطني للتیقظ والسلامة الدوائیة&nbsp;<br />فاكس+۹٦٦۱۱۲۰٥۷٦٦۲:&nbsp;<br />ھاتف مجاني: ۸۰۰۲٤۹۰۰۰۰<br />تلفون: ۰۰۹٦٦-۱۱-۲۰۳۸۲۲۲<br />تحویلة: ،۲۳٥۳ ،۲۳٥٦ ،۲۳۱۷ ،۲۳٥٤ ،۲۳۳٤ ۲۳٤۰<br />npc.drug@sfda.gov.sa : الألكتروني البرید<br />www.sfda.gov.sa/npc : الألكتروني الموقع</p><p>دول الخلیج الأخرى:<br />الرجاء الاتصال بالمؤسسات والھیئات الوطنیة في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biocaffcit
 “Caffeine Citrate 20mg/ml solution for infusion and oral solution”
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 20 mg caffeine citrate (equivalent to 10 mg caffeine).
Each 3 ml Vial contains 60 mg caffeine citrate (equivalent to 30 mg caffeine).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
Oral solution.
Appearance: Clear and colourless.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of primary apnoea of premature newborns.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Biocaffcit should be initiated under the supervision of a physician&nbsp;<br />experienced in neonatal intensive care. Treatment should be administered only in a&nbsp;<br />neonatal intensive care unit in which adequate facilities are available for patient&nbsp;<br />surveillance and monitoring.&nbsp;<br />Posology<br />The recommended dose regimen in previously untreated infants is a loading dose of 20&nbsp;<br />mg caffeine citrate per kg body weight administered by slow intravenous infusion over&nbsp;<br />30 minutes, using a syringe infusion pump or other metered infusion device. After an&nbsp;<br />interval of 24 hours, maintenance doses of 5 mg per kg body weight may be&nbsp;<br />administered by slow intravenous infusion over 10 minutes every 24 hours.&nbsp;<br />Alternatively, maintenance doses of 5 mg per kg body weight may be administered by&nbsp;<br />oral administration, such as through a nasogastric tube every 24 hours.&nbsp;<br />The recommended loading dose and maintenance doses of caffeine citrate are provided&nbsp;<br />in the following table which clarifies the relationship between injection volumes and&nbsp;<br />administered doses expressed as caffeine citrate.&nbsp;<br />The dose expressed as caffeine base is one-half the dose when expressed as caffeine&nbsp;<br />citrate (20 mg caffeine citrate are equivalent to 10 mg caffeine base).&nbsp;<br />&nbsp;</p><table border="1" cellspacing="1" cellpadding="0" style="width:698px"><tbody><tr><td>&nbsp;</td><td><p>Dose of Biocaffcit 10mg/ml Solution for Injection</p></td><td><p>Dose Expressed as Caffeine Citrate</p></td><td><p>Dose Expressed as Caffeine Base</p></td><td><p>Route</p></td><td><p>Frequency</p></td></tr><tr><td><p>Loading Dose See (b) above</p></td><td><p>2ml/kg</p></td><td><p>20 mg/kg</p></td><td><p>10mg/kg</p></td><td><p>Intravenous** (over 30 min) or oral</p></td><td><p>Once</p></td></tr><tr><td><p>Maintenance Dose</p></td><td><p>0.5-1ml/kg*</p></td><td><p>5-10mg/kg*</p></td><td><p>2.5-5.0mg/kg*</p></td><td><p>Intravenous** (over 10 min) or oral</p></td><td><p>Every 24 hours***</p></td></tr></tbody></table><p>* Beginning 24 hours after the loading dose</p><p>In preterm newborn infants with insufficient clinical response to the recommended&nbsp;<br />loading dose, a second loading dose of 10 -20 mg/kg maximum may be given after 24&nbsp;<br />hours.&nbsp;<br />Higher maintenance doses of 10 mg/kg body weight could be considered in case of&nbsp;<br />insufficient response, taking into account the potential for accumulation of caffeine due&nbsp;<br />to the long half- life in preterm newborn infants and the progressively increasing&nbsp;<br />capacity to metabolise caffeine in relation to post-menstrual age (see section 5.2).&nbsp;<br />Where clinically indicated, caffeine plasma levels should be monitored. The diagnosis&nbsp;<br />of apnoea of prematurity may need to be reconsidered if patients do not respond&nbsp;<br />adequately to a second loading dose or maintenance dose of 10 mg/kg/day (see section&nbsp;<br />4.4).</p><p>&nbsp;</p><p><strong>Dosage adjustments and monitoring</strong><br />Plasma concentrations of caffeine may need to be monitored periodically throughout&nbsp;<br />treatment in cases of incomplete clinical response or signs of toxicity.&nbsp;<br />Additionally, doses may need to be adjusted according to medical judgment following&nbsp;<br />routine monitoring of caffeine plasma concentrations in at risk situations such as:<br />- very premature infants (&lt; 28 weeks gestational age and/or body weight &lt;1000 g)&nbsp;<br />particularly when receiving parenteral nutrition&nbsp;<br />- infants with hepatic and renal impairment (see sections 4.4 and 5.2)&nbsp;<br />- infants with seizure disorders<br />- infants with known and clinically significant cardiac disease<br />- infants receiving co-administration of medicinal products known to interfere with&nbsp;<br />caffeine metabolism (see section 4.5)<br />- infants whose mothers consume caffeine while providing breast milk for feeding.<br />It is advisable to measure baseline caffeine levels in:<br />- infants whose mothers may have ingested large quantities of caffeine prior to delivery&nbsp;<br />(see section 4.4)<br />- infants who have previously been treated with theophylline, which is metabolized to&nbsp;caffeine.<br />Caffeine has a prolonged half-life in premature newborn infants and there is potential&nbsp;<br />for accumulation which may necessitate monitoring infants treated for an extended&nbsp;<br />period (see section 5.2).<br />Blood samples for monitoring should be taken just before the next dose in the case of&nbsp;<br />therapeutic failure and 2 to 4 hours after the previous dose when suspecting toxicity.<br />Although a therapeutic plasma concentration range of caffeine has not been determined&nbsp;<br />in the literature, caffeine levels in studies associated with clinical benefit ranged from 8&nbsp;<br />to 30 mg/l and no safety concerns have normally been raised with plasma levels below&nbsp;<br />50 mg/l.&nbsp;</p><p>&nbsp;</p><p><strong>Duration of treatment&nbsp;</strong><br />The optimal duration of treatment has not been established. In a recent large&nbsp;<br />multicentre study on preterm newborn infants a median treatment period of 37 days&nbsp;<br />was reported.&nbsp;<br />In clinical practice, treatment is usually continued until the infant has reached a postmenstrual age of 37 weeks, by which time apnoea of prematurity usually resolves&nbsp;<br />spontaneously. This limit may however be revised according to clinical judgment in&nbsp;<br />individual cases depending on the response to treatment, the continuing presence of&nbsp;<br />apnoeic episodes despite treatment, or other clinical considerations. It is recommended&nbsp;<br />that caffeine citrate administration should be stopped when the patient has 5-7 days&nbsp;<br />without a significant apnoeic attack.&nbsp;<br />If the patient has recurrent apnoea, caffeine citrate administration can be restarted with&nbsp;<br />either a maintenance dose or a half loading dose, depending upon the time interval&nbsp;<br />from stopping caffeine citrate to recurrence of apnoea.<br />Because of the slow elimination of caffeine in this patient population, there is no&nbsp;<br />requirement for dose tapering on cessation of treatment.&nbsp;<br />As there is a risk for recurrence of apnoeas after cessation of caffeine citrate treatment&nbsp;<br />monitoring of the patient should be continued for approximately one week.</p><p>&nbsp;</p><p><strong>Hepatic and renal impairment&nbsp;</strong><br />There is limited experience in patients with renal and hepatic impairment. In a post&nbsp;<br />authorisation safety study, the frequency of adverse reactions in a small number of very&nbsp;<br />premature infants with renal/hepatic imparment appeared to be higher as compared to&nbsp;<br />premature infants without organ impairment (see sections 4.4 and 4.8).<br />In the presence of renal impairment, there is increased potential for accumulation. A&nbsp;<br />reduced daily maintenance dose of caffeine citrate is required and the dose should be&nbsp;<br />guided by plasma caffeine measurements.&nbsp;<br />In very premature infants, clearance of caffeine does not depend on hepatic function.&nbsp;<br />Hepatic caffeine metabolism develops progressively in the weeks following birth and&nbsp;<br />for the older infants, hepatic disease may indicate a need for monitoring caffeine&nbsp;<br />plasma levels and may require dose adjustments (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><strong>Method of administration</strong><br />Caffeine citrate can be administered by intravenous infusion and by the oral route. The&nbsp;<br />medicinal product must not be administered by intramuscular, subcutaneous,&nbsp;<br />intrathecal or intraperitoneal injection.<br />When given intravenously, caffeine citrate should be administered by controlled&nbsp;<br />intravenous infusion, using a syringe infusion pump or other metered infusion device&nbsp;<br />only. Caffeine citrate can be either used without dilution or diluted in sterile solutions&nbsp;<br />for infusion such as glucose 50 mg/ml (5%) or sodium chloride 9 mg/ml (0.9%) or&nbsp;<br />calcium gluconate 100 mg/ml (10%) immediately after withdrawal from the vial (see&nbsp;<br />section 6.6).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Apnoea</strong><br />Apnoea of prematurity is a diagnosis of exclusion. Other causes of apnoea (e.g., central&nbsp;<br />nervous system disorders, primary lung disease, anaemia, sepsis, metabolic&nbsp;<br />disturbances, cardiovascular abnormalities, or obstructive apnoea) should be ruled out&nbsp;<br />or properly treated prior to initiation of treatment with caffeine citrate. Failure to&nbsp;<br />respond to caffeine treatment (confirmed if necessary by measurement of plasma&nbsp;<br />levels) could be an indication of another cause of apnoea.</p><p><strong>Caffeine consumption</strong><br />In newborn infants born to mothers who consumed large quantities of caffeine prior to&nbsp;<br />delivery, baseline plasma caffeine concentrations should be measured prior to initiation&nbsp;<br />of treatment with caffeine citrate, since caffeine readily crosses the placenta into the&nbsp;<br />foetal circulation (see sections 4.2 and 5.2).<br />Breast-feeding mothers of newborn infants treated with caffeine citrate should not&nbsp;<br />ingest caffeine-containing foods and beverages or medicinal products containing&nbsp;<br />caffeine (see section 4.6), since caffeine is excreted into breast milk (see section 5.2).&nbsp;</p><p><strong>Theophylline</strong><br />In newborns previously treated with theophylline, baseline plasma caffeine&nbsp;<br />concentrations should be measured prior to initiation of treatment with caffeine citrate&nbsp;<br />because preterm infants metabolise theophylline to caffeine.&nbsp;<br />Seizures<br />Caffeine is a central nervous system stimulant and seizures have been reported in cases&nbsp;<br />of caffeine overdose. Extreme caution must be exercised if caffeine citrate is used in&nbsp;<br />newborns with seizure disorders.</p><p><strong>Cardiovascular reactions</strong><br />Caffeine has been shown to increase heart rate, left ventricular output, and stroke&nbsp;<br />volume in published studies. Therefore, caffeine citrate should be used with caution in&nbsp;<br />newborns with known cardiovascular disease. There is evidence that caffeine causes&nbsp;<br />tachyarrhythmias in susceptible individuals. In newborns this is usually a simple sinus&nbsp;<br />tachycardia. If there have been any unusual rhythm disturbances on a cardiotocograph&nbsp;<br />(CTG) trace before the baby is born, caffeine citrate should be administered with&nbsp;<br />caution.</p><p><strong>Renal and hepatic impairment</strong><br />Caffeine citrate should be administered with caution in preterm newborn infants with&nbsp;<br />impaired renal or hepatic function. In a post-authorisation safety study, the frequency&nbsp;<br />of adverse reactions in a small number of very premature infants with renal/hepatic&nbsp;<br />impairment appeared to be higher as compared to premature infants without organ&nbsp;<br />impairment (see sections 4.2, 4.8 and 5.2). Doses should be adjusted by monitoring of&nbsp;<br />caffeine plasma concentrations to avoid toxicity in this population.</p><p><strong>Necrotising enterocolitis</strong><br />Necrotising enterocolitis is a common cause of morbidity and mortality in premature&nbsp;<br />newborn infants. There are reports of a possible association between the use of methylxanthines and development of necrotising enterocolitis. However, a causal&nbsp;<br />relationship between caffeine or other methylxanthine use and necrotising enterocolitis&nbsp;<br />has not been established. As for all preterm infants, those treated with caffeine citrate&nbsp;<br />should be carefully monitored for the development of necrotising enterocolitis (see&nbsp;<br />section 4.8).&nbsp;<br />Caffeine citrate should be used with caution in infants suffering gastro-oesophageal&nbsp;<br />reflux, as the treatment may exacerbate this condition.<br />Caffeine citrate causes a generalised increase in metabolism, which may result in&nbsp;<br />higher energy and nutrition requirements during therapy.&nbsp;<br />The diuresis and electrolyte loss induced by caffeine citrate may necessitate correction&nbsp;<br />of fluid and electrolyte disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inter-conversion between caffeine and theophylline occurs in preterm newborn infants.&nbsp;<br />These active substances should not be used concurrently.&nbsp;<br />Cytochrome P450 1A2 (CYP1A2) is the major enzyme involved in the metabolism of&nbsp;<br />caffeine in humans. Therefore, caffeine has the potential to interact with active&nbsp;<br />substances that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.&nbsp;<br />However, caffeine metabolism in preterm newborn infants is limited due to their&nbsp;<br />immature hepatic enzyme systems.<br />Although few data exist on interactions of caffeine with other active substances in&nbsp;<br />preterm newborn infants, lower doses of caffeine citrate may be needed following coadministration of active substances which are reported to decrease caffeine elimination&nbsp;<br />in adults (e.g., cimetidine and ketoconazole) and higher caffeine citrate doses may be&nbsp;<br />needed following co-administration of active substances that increase caffeine&nbsp;<br />elimination (e.g., phenobarbital and phenytoin). Where doubt exists about possible&nbsp;<br />interactions, plasma caffeine concentrations should be measured.<br />As bacterial overgrowth in the gut is associated with the development of necrotising&nbsp;<br />enterocolitis, co-administration of caffeine citrate with medicinal products that suppress&nbsp;<br />gastric acid secretion (antihistamine H2 receptor blockers or proton-pump inhibitors)&nbsp;<br />may in theory increase the risk of necrotising enterocolitis (see section 4.4 and 4.8).<br />Concurrent use of caffeine and doxapram might potentiate their stimulatory effects on&nbsp;<br />the cardio-respiratory and central nervous system. If concurrent use is indicated,&nbsp;<br />cardiac rhythm and blood pressure must be carefully monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Caffeine in animal studies, at high doses, was shown to be embryotoxic and&nbsp;<br />teratogenic. These effects are not relevant with regard to short term administration in&nbsp;<br />the preterm infant population (see section 5.3).</p><p><strong>Breast-feeding</strong><br />Caffeine is excreted into breast milk and readily crosses the placenta into the foetal&nbsp;<br />circulation (see section 5.2).<br />Breast-feeding mothers of newborn infants treated with caffeine citrate should not&nbsp;<br />ingest caffeine-containing foods, beverages or medicinal products containing caffeine.<br />In newborn infants born to mothers who consumed large quantities of caffeine prior to&nbsp;<br />delivery, baseline plasma caffeine concentrations should be measured prior to initiation&nbsp;<br />of treatment with caffeine citrate (see section 4.4).</p><p><strong>Fertility</strong><br />Effects on reproductive performance observed in animals are not relevant to its&nbsp;<br />indication in the preterm newborn infants (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Summary of the safety profile</strong></u><br />The known pharmacology and toxicology of caffeine and other methylxanthines predict&nbsp;<br />the likely adverse reactions to caffeine citrate. Effects described include central nervous&nbsp;<br />system (CNS) stimulation such as convulsion, irritability, restlessness and jitteriness,&nbsp;<br />cardiac effects such as tachycardia, arrhythmia, hypertension and increased stroke&nbsp;<br />volume, metabolism and nutrition disorders such as hyperglycaemia. These effects are&nbsp;<br />dose related and may necessitate measurement of plasma levels and dose reduction.</p><p><u><strong>Tabulated list of adverse reactions</strong></u><br />The adverse reactions described in the short- and long-term published literature and&nbsp;<br />obtained from a post-authorisation safety study that can be associated with caffeine&nbsp;<br />citrate are listed below by System Organ Class and Preferred Term (MedDRA).&nbsp;<br />Frequency is defined as: very common (&ge; 1/10), common (&ge;1/100 to &lt;1/10),&nbsp;<br />uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000)&nbsp;<br />and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="0" style="width:728px"><tbody><tr><td><p>System Organ Class</p></td><td><p>Adverse Reaction</p></td><td><p>Frequency</p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>Sepsis</p></td><td><p>Not known</p></td></tr><tr><td><p>Immune system disorders</p></td><td><p>Hypersensitivity reaction</p></td><td><p>Rare</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Hyperglycaemia</p><p>Hypoglycaemia, failure to thrive, feeding intolerance</p></td><td><p>Common</p><p>Not known</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Convulsion</p><p>Irritability, jitteriness, restlessness, brain injury</p></td><td><p>Uncommon</p><p>Not known</p></td></tr><tr><td><p>Ear and labyrinth disorders</p></td><td><p>Deafness</p></td><td><p>Not known</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Tachycardia</p><p>Arrhythmia</p><p>Increased left ventricular output and increased stroke volume</p></td><td><p>Common</p><p>Uncommon</p><p>Not known</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Regurgitation, increased gastric aspirate, necrotising enterocolitis</p></td><td><p>Not known</p></td></tr><tr><td><p>General disorders and</p></td><td><p>Infusion site phlebitis, infusion site</p></td><td><p>Common</p></td></tr><tr><td><p>administration site conditions</p></td><td><p>inflammation</p></td><td>&nbsp;</td></tr><tr><td><p>Investigations</p></td><td><p>Urine output increased, urine sodium and calcium increased, haemoglobin decreased, thyroxine decreased</p></td><td><p>Not known</p></td></tr></tbody></table><p>&nbsp;</p><p><u><strong>Description of selected adverse reactions&nbsp;</strong></u><br />Necrotising enterocolitis is a common cause of morbidity and mortality in premature&nbsp;<br />newborn infants. There are reports of a possible association between the use of&nbsp;<br />methylxanthines and development of necrotising enterocolitis. However, a causal&nbsp;<br />relationship between caffeine or other methylxanthine use and necrotising enterocolitis&nbsp;<br />has not been established.&nbsp;<br />In a double-blind placebo-controlled study of caffeine citrate in 85 preterm infants (see&nbsp;<br />section 5.1), necrotising enterocolitis was diagnosed in the blinded phase of the study&nbsp;<br />in two infants on active treatment and one on placebo, and in three infants on caffeine&nbsp;<br />during the open-label phase of the study. Three of the infants who developed&nbsp;<br />necrotising enterocolitis during the study died. A large multicentre study (n=2006)&nbsp;<br />investigating long-term outcome of premature infants treated with caffeine citrate (see&nbsp;<br />section 5.1) did not show an increased frequency of necrotising enterocolitis in the&nbsp;</p><p>caffeine group when compared to placebo. As for all preterm infants, those treated with&nbsp;<br />caffeine citrate should be carefully monitored for the development of necrotising&nbsp;<br />enterocolitis (see section 4.4).&nbsp;<br />Brain injury, convulsion and deafness were observed but they were more frequent in&nbsp;<br />the placebo group.<br />Caffeine may suppress erythropoietin synthesis and hence reduce haemoglobin&nbsp;<br />concentration with prolonged treatment.<br />Transient falls in thyroxine (T4) have been recorded in infants at the start of therapy&nbsp;<br />but these are not sustained with maintained therapy.<br />Available evidence does not indicate any adverse long-term reactions of neonatal&nbsp;<br />caffeine therapy as regards neurodevelopmental outcome, failure to thrive or on the&nbsp;<br />cardiovascular, gastrointestinal or endocrine systems. Caffeine does not appear to&nbsp;<br />aggravate cerebral hypoxia or to exacerbate any resulting damage, although the&nbsp;<br />possibility cannot be ruled out.</p><p><br /><u><strong>Other special populations</strong></u><br />In a post-authorisation safety study on 506 preterm infants treated with Peyona, safety&nbsp;<br />data have been collected in 31 very premature infants with renal/hepatic impairment.&nbsp;<br />Adverse reactions appeared to be more frequent in this subgroup with organ&nbsp;<br />impairment than in other observed infants without organ impairment. Cardiac disorders&nbsp;<br />(tachycardia, including one single case of arrhythmia) were mostly reported.<br />To report any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;<br />&nbsp;Fax: +966-11-205-7662&nbsp;<br />&nbsp;Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.&nbsp;<br />&nbsp;Toll free phone: 8002490000&nbsp;<br />&nbsp;E-mail: npc.drug@sfda.gov.sa&nbsp;<br />&nbsp;Website: www.sfda.gov.sa/npc&nbsp;<br />&nbsp;Other GCC States:&nbsp;<br />&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following overdose, published plasma caffeine levels have ranged from approximately&nbsp;<br />50 mg/l to 350 mg/l.&nbsp;<br />&nbsp;</p><p><u><strong>Symptoms</strong></u><br />Signs and symptoms reported in the literature after caffeine overdose in preterm infants&nbsp;<br />include hyperglycaemia, hypokalaemia, fine tremor of the extremities, restlessness, hypertonia, opisthotonus, tonic clonic movements, seizures, tachypnoea, tachycardia,&nbsp;<br />vomiting, gastric irritation, gastro-intestinal haemorrhage, pyrexia, jitteriness, increased&nbsp;<br />blood urea and increased white blood cell count, non-purposeful jaw and lip&nbsp;<br />movements. One case of caffeine overdose complicated by development of&nbsp;<br />intraventricular haemorrhage and long-term neurological sequelae has been reported.&nbsp;<br />No deaths associated with caffeine overdose have been reported in preterm infants.<br />&nbsp;</p><p><u><strong>Management</strong></u><br />Treatment of caffeine overdose is primarily symptomatic and supportive. Plasma&nbsp;<br />potassium and glucose concentrations should be monitored and hypokalaemia and&nbsp;<br />hyperglycaemia corrected. Plasma caffeine concentrations have been shown to decrease&nbsp;<br />after exchange transfusion. Convulsions may be treated with intravenous administration&nbsp;<br />of anticonvulsants (diazepam or a barbiturate such as pentobarbital sodium or&nbsp;<br />phenobarbital).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psychoanaleptics, xanthine derivatives&nbsp;<br />ATC code: N06BC01<br />Mechanism of action<br />Caffeine is structurally related to the methylxanthines theophylline and theobromine.&nbsp;<br />Most of its effects have been attributed to antagonism of adenosine receptors, both A1<br />and A2A subtypes, demonstrated in receptor binding assays and observed at&nbsp;<br />concentrations approximating those achieved therapeutically in this indication.<br />Pharmacodynamic effects<br />Caffeine&#39;s main action is as a CNS stimulant. This is the basis of caffeine&#39;s effect in&nbsp;<br />apnoea of prematurity, for which several mechanisms have been proposed for its&nbsp;<br />actions including: (1) respiratory centre stimulation, (2) increased minute ventilation,&nbsp;<br />(3) decreased threshold to hypercapnia, (4) increased response to hypercapnia, (5)&nbsp;<br />increased skeletal muscle tone, (6) decreased diaphragmatic fatigue, (7) increased&nbsp;<br />metabolic rate, and (8) increased oxygen consumption.&nbsp;<br />Clinical efficacy and safety<br />The clinical efficacy of caffeine citrate was assessed in a multicentre, randomised,&nbsp;<br />double-blind study that compared caffeine citrate to placebo in 85 preterm infants&nbsp;<br />(gestational age 28 to &lt;33 weeks) with apnoea of prematurity. Infants received 20&nbsp;<br />mg/kg caffeine citrate loading dose intravenously. A maintenance daily dose of 5 mg/kg caffeine citrate was then administered either intravenously or orally (through a&nbsp;<br />feeding tube) for up to 10-12 days. The protocol allowed infants to be &ldquo;rescued&rdquo; with&nbsp;<br />open-label caffeine citrate treatment if their apnoea remained uncontrolled. In that case,&nbsp;<br />infants received a second loading dose of 20 mg/kg caffeine citrate after treatment day&nbsp;<br />1 and before treatment day 8.&nbsp;<br />There were more days without any apnoea under caffeine citrate treatment (3.0 days,&nbsp;<br />versus 1.2 days for placebo; p=0.005); also, there was a higher percentage of patients&nbsp;<br />with no apnoeas for &ge; 8 days (caffeine 22% versus placebo 0%).&nbsp;<br />A recent large placebo-controlled multicentre study (n=2006) investigated short-term&nbsp;<br />and long-term (18-21 months) outcomes of premature infants treated with caffeine&nbsp;<br />citrate. Infants randomised to caffeine citrate received an intravenous loading dose of&nbsp;<br />20 mg/kg, followed by a daily maintenance dose of 5 mg/kg. If apnoeas persisted, the&nbsp;<br />daily maintenance dose could be increased to a maximum of 10 mg/kg of caffeine&nbsp;<br />citrate. The maintenance doses were adjusted weekly for changes in body weight and&nbsp;<br />could be given orally once an infant tolerated full enteral feedings. Caffeine therapy&nbsp;<br />reduced the rate of bronchopulmonary dysplasia [odds ratio (95% CI) 0.63 (0.52 to&nbsp;<br />0.76)] and improved the rate of survival without neurodevelopmental disability [odds&nbsp;<br />ratio (95 %CI) 0.77 (0.64 to 0.93)].&nbsp;</p><p>The size and direction of caffeine effect on death and disability differed depending on&nbsp;<br />the degree of respiratory support infants needed at randomisation, indicating more&nbsp;<br />benefit for the supported infants [odds ratio (95%CI) for death and disability, see table&nbsp;<br />below].<br />Death or disability according to subgroup of respiratory support at entry to study</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Subgroups</td><td>Odds ratio (95% CI)</td></tr><tr><td>No support</td><td>1.32 (0.81 to 2.14)</td></tr><tr><td>Non invasive support</td><td>0.73 (0.52 to 1.03)</td></tr><tr><td>Endotracheal tube</td><td>0.73 (0.57 to 0.94)</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Caffeine citrate readily dissociates in aqueous solution. The citrate moiety is rapidly&nbsp;<br />metabolized on infusion or ingestion.&nbsp;</p><p><strong>Absorption</strong><br />The onset of action of caffeine from caffeine citrate is within minutes of&nbsp;<br />commencement of infusion. After oral administration of 10 mg caffeine base/kg body&nbsp;<br />weight to preterm newborn infants, the peak plasma caffeine concentration (Cmax)&nbsp;<br />ranged from 6 to 10 mg/l and the mean time to reach peak concentration (tmax) ranged&nbsp;<br />from 30 min to 2 h. The extent of absorption is not affected by formula feeding but tmax&nbsp;<br />may be prolonged.</p><p><strong>Distribution</strong><br />Caffeine is rapidly distributed into the brain following caffeine citrate administration.&nbsp;<br />Caffeine concentrations in the cerebrospinal fluid of preterm newborn infants&nbsp;<br />approximate to their plasma levels. The mean volume of distribution (Vd) of caffeine in&nbsp;<br />infants (0.8-0.9 l/kg) is slightly higher than that in adults (0.6 L/kg). Plasma protein&nbsp;<br />binding data are not available for newborn infants or infants. In adults, the mean&nbsp;<br />plasma protein binding in vitro is reported to be approximately 36%.&nbsp;<br />Caffeine readily crosses the placenta into the fetal circulation and is excreted into&nbsp;<br />breast milk.</p><p><strong>Biotransformation</strong><br />Caffeine metabolism in preterm newborn infants is very limited due to their immature&nbsp;<br />hepatic enzyme systems and most of the active substance is eliminated in urine.&nbsp;<br />Hepatic cytochrome P450 1A2 (CYP1A2) is involved in caffeine biotransformation in&nbsp;<br />older individuals.<br />Inter-conversion between caffeine and theophylline has been reported in preterm&nbsp;<br />newborn infants; caffeine levels are approximately 25% of theophylline levels after&nbsp;<br />theophylline administration and approximately 3-8% of caffeine administered would be&nbsp;<br />expected to convert to theophylline.&nbsp;</p><p><strong>Elimination</strong><br />In young infants, the elimination of caffeine is much slower than that in adults due to&nbsp;<br />immature hepatic and/or renal function. In newborn infants, caffeine clearance is&nbsp;<br />almost entirely by renal excretion. Mean half-life (t1/2) and fraction excreted unchanged&nbsp;<br />in urine (Ae) of caffeine in infants are inversely related to gestational / postmenstrual&nbsp;<br />age. In newborn infants, the t1/2 is approximately 3-4 days and the Ae is approximately&nbsp;<br />86% (within 6 days). By 9 months of age, the metabolism of caffeine approximates to&nbsp;<br />that seen in adults (t1/2 = 5 hours and Ae = 1%).&nbsp;<br />Studies examining the pharmacokinetics of caffeine in newborn infants with hepatic or&nbsp;<br />renal insufficiency have not been conducted.&nbsp;<br />In the presence of significant renal impairment, considering the increased potential for&nbsp;<br />accumulation, a reduced daily maintenance dose of caffeine is required and the doses&nbsp;<br />should be guided by blood caffeine measurements. In premature infants with&nbsp;<br />cholestatic hepatitis a prolonged caffeine elimination half-life with an increase of&nbsp;<br />plasma levels above the normal limit of variation has been found suggesting a&nbsp;<br />particular caution in the dosage of these patients (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no major hazard for humans based on studies of repeated&nbsp;<br />dose toxicity of caffeine. However, at high doses convulsions in rodents were induced.&nbsp;<br />At therapeutic doses some behavioural changes in newborn rats were induced, most<br />likely as a consequence of increased adenosine receptor expression that persisted into&nbsp;<br />adulthood. Caffeine was shown to be devoid of mutagenic and oncogenic risk.&nbsp;<br />Teratogenic potential and effects on reproductive performance observed in animals are&nbsp;<br />not relevant to its indication in the preterm infant population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Citric acid monohydrate : 5.0 mg/ml<br />- Sodium citrate Dihydrate : 8.30 mg/ml<br />- Water For Injections to 1 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed or concomitantly administered in the same&nbsp;intravenous line with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 Months
After opening the Vial, the medicinal product should be used immediately.
In case of dilution, the diluted solution could be stored at temperature 25°C or 
between 2-8°C, and used within 24 hours of dilution.
From a microbiological point of view, when administered with solutions for infusion 
the medicinal product should be used immediately after dilution by aseptic technique.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.<br />For storage conditions of the diluted medicinal product see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear glass Vial containing 3 ml Solution<br />Pack size: 10 Glass vials / Pack&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aseptic technique must be strictly observed throughout handling of the medicinal&nbsp;<br />product since no preservative is present.<br />This Product should be inspected visually for particulate matter and discoloration prior&nbsp;<br />to administration. Vials containing discoloured solution or visible particulate matter&nbsp;<br />should be discarded.<br />This Product can be either used without dilution or diluted in sterile solutions for&nbsp;<br />infusion such as 5% glucose or 0.9% sodium chloride or 10% calcium Gluconate&nbsp;<br />immediately after withdrawal from the Vial.<br />The diluted solution must be clear and colourless. Undiluted and diluted parenteral&nbsp;<br />solutions must be inspected visually for particulate matter and discoloration prior to&nbsp;<br />administration. The solution must not be used if it is discoloured or foreign particulate&nbsp;<br />matter is present.<br />For single use only. Any unused portion left in the Vial should be discarded. Unused&nbsp;<br />portions should not be saved for later administration.<br />No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharmaceutical Solutions Industry Ltd.
Industrial Estate, Phase-2, 
Road No. 208, Str. - 203
P O Box 17476
Jeddah 21484
Western Province
Saudi Arabia
Phone: +966-12-6361383
FAX: +966-12-6379460
Website: http://www.psiltd.com

To report any side effect(s):

For Saudi Arabia:

The National Pharmacovigilance and Drug Safety Centre (NPC)

* Fax: +966-11-205-7662

* Reporting hotline: 19999.

* E-mail: npc.drug@sfda.gov.sa

* Website: www.sfda.gov.sa/npc

Other GCC States:
Please contact the relevant competent authority
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>